MedPath

Dapsone

Generic Name
Dapsone
Brand Names
Aczone
Drug Type
Small Molecule
Chemical Formula
C12H12N2O2S
CAS Number
80-08-0
Unique Ingredient Identifier
8W5C518302
Background

A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)

Indication

For the treatment and management of leprosy and dermatitis herpetiformis.

Associated Conditions
Acne Vulgaris, Bullous Systemic Lupus Erythematosus, Bullous dermatitis herpetiformis, Hansen's Disease, Pemphigus Vulgaris (PV), Relapsing Polychondritis, Mild Pneumocystis pneumonia, Mild Toxoplasma gondii encephalitis, Moderate Pneumocystis pneumonia, Moderate Toxoplasma gondii encephalitis, Refractory Idiopathic thrombocytopenic purpura
Clinical Trials
Related News

Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients

Not Applicable
Recruiting
Conditions
Mycobacterium Leprae Infection
Leprosy
Interventions
First Posted Date
2025-02-11
Last Posted Date
2025-02-11
Lead Sponsor
South Valley University
Target Recruit Count
50
Registration Number
NCT06819449
Locations
🇪🇬

Qina University hospital, South Valley University Hospital, Qina, Egypt

Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid

Phase 4
Recruiting
Conditions
Bullous Pemphigoid
Interventions
First Posted Date
2023-08-09
Last Posted Date
2023-12-13
Lead Sponsor
All India Institute of Medical Sciences, Bhubaneswar
Target Recruit Count
62
Registration Number
NCT05984381
Locations
🇮🇳

AIIMS Bhubaneswar, Bhubaneswar, Odisha, India

DAPSONE GEL7.5%Versus Trichloroacetic Acid 20% ON ACNE VULGARIS

Phase 4
Conditions
Acne Vulgaris
Interventions
First Posted Date
2022-03-25
Last Posted Date
2022-04-01
Lead Sponsor
Assiut University
Target Recruit Count
30
Registration Number
NCT05296460

Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.

Phase 3
Completed
Conditions
Subarachnoid Hemorrhage
Brain Ischemia
Subarachnoid Hemorrhage, Aneurysmal
Aneurysmal Subarachnoid Hemorrhage
Delayed Cerebral Ischemia
Vasospasm, Cerebral
Interventions
First Posted Date
2021-11-23
Last Posted Date
2021-11-23
Lead Sponsor
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Target Recruit Count
49
Registration Number
NCT05131295
Locations
🇲🇽

El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Mexico City, Mexico

Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19

Phase 3
Conditions
COVID-19
Interventions
Drug: Placebo 85 mg PO BID
First Posted Date
2021-06-23
Last Posted Date
2022-02-24
Lead Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Target Recruit Count
3000
Registration Number
NCT04935476
Locations
🇨🇦

McGill University Health Centre, Montreal, Quebec, Canada

🇺🇸

University of Pittsburgh UPMC, Pittsburgh, Pennsylvania, United States

🇺🇸

Arizona Pulmonary and Medical Specialists, Phoenix, Arizona, United States

and more 4 locations

Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment

Early Phase 1
Conditions
SARS-CoV-2
Hypoxia
ARDS
Interventions
First Posted Date
2021-06-09
Last Posted Date
2021-06-09
Lead Sponsor
Hunt Regional Medical Center
Target Recruit Count
100
Registration Number
NCT04918914
Locations
🇺🇸

Hunt Regional Medical Center, Greenville, Texas, United States

Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Phase 3
Completed
Conditions
Acne Vulgaris
Interventions
Other: Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)
First Posted Date
2019-07-11
Last Posted Date
2020-04-02
Lead Sponsor
Torrent Pharmaceuticals Limited
Target Recruit Count
1150
Registration Number
NCT04015375
Locations
🇧🇿

Dermatology & Skin Surgery Centre/ FXM Research International, Belize City, Belize

🇧🇿

Dr. Moguel's Clinic/ FXM Research International, Belize City, Belize

🇺🇸

Unison Center for Clinical Trials, Sherman Oaks, California, United States

and more 10 locations

Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color

Phase 4
Completed
Conditions
Acne Vulgaris
Interventions
First Posted Date
2018-09-24
Last Posted Date
2022-07-27
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
20
Registration Number
NCT03681470
Locations
🇺🇸

Mount Sinai West, New York, New York, United States

Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Phase 1
Completed
Conditions
Acne Vulgaris
Interventions
Drug: Placebo
Drug: DPSG 7.5%
First Posted Date
2017-04-27
Last Posted Date
2017-05-04
Lead Sponsor
Taro Pharmaceuticals USA
Target Recruit Count
1125
Registration Number
NCT03132194

Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

Phase 4
Completed
Conditions
Acne Vulgaris
Interventions
First Posted Date
2016-11-09
Last Posted Date
2020-03-03
Lead Sponsor
Almirall, S.A.
Target Recruit Count
100
Registration Number
NCT02959970
Locations
🇺🇸

Redwood Family Dermatology, Santa Rosa, California, United States

🇺🇸

Skin Specialists, PC, Omaha, Nebraska, United States

🇺🇸

DermResearch, LLC, Austin, Texas, United States

and more 17 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy